ArticleEClinicalMedicine2022
Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study.
Article in EClinicalMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Factors influencing the survival of patients with advanced HIV disease in Guinea from 2015 to 2024.BMC public health · 2026Article
- A combined eGFR-CD4 index and mortality risk among people with HIV: a retrospective cohort study in Taizhou city, Zhejiang province, China.AIDS research and therapy · 2026Article
- Quantifying Direct and Indirect Effects through Joint Modeling of Terminal Events and Gap Times between Recurrent Events.Journal of data science : JDS · 2026Article
- Expert consensus on the clinical management of HIV late presentation.Infectious diseases & immunity · 2026Article
- Risk factors for late HIV diagnosis in England, 2015-2023.HIV medicine · 2026Article
- Pathological Proliferation of CD4Infection and drug resistance · 2026Article
- Nucleic acid testing-optimized HIV diagnostic algorithms: a multimethod comparative effectiveness analysis in clinical practice.British journal of biomedical science · 2026Article
- Immune reconstitution and long-term survival outcomes in LTHIs and TPs living with long-term ART: a propensity score-matched cohort study in Xinjiang, China.Frontiers in public health · 2026Article
- Nomogram model for predicting incomplete immune reconstitution in people living with HIV based on clinical characteristics.Frontiers in immunology · 2026Article
- Protective association of theFrontiers in medicine · 2026Article
- Factors mediating and associated with immunological response in women living with HIV in Sweden: A nationwide register-based study.HIV medicine · 2025Article
- Gut microbiota metabolites impact immunologic responses to antiretroviral therapy in HIV-infected men who have sex with men.Infectious diseases of poverty · 2025Article
- Predictors of loss to follow-up among people living with HIV on antiretroviral therapy in a rural health facility using paper-based records.Frontiers in public health · 2025Article
- Association between late access to care and mortality for PWH: insights from the French Hospital Database on HIV (ANRS CO4-FHDH) from 2002 to 2016.BMJ public health · 2025Article
- Has COVID-19 Changed the Incidence and Profile of Late Presenters for HIV Infection in Lodz, Polish Reference Centre, Poland?Journal of clinical medicine · 2024Article
- Progress in Early Detection of HIV in Tajikistan.Viruses · 2024Article
- Risk Factors for Late HIV Presentation in Patients Treated at a Single Belgian Reference Centre from 2018 to 2022.Infectious disease reports · 2024Article
- Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort study.Frontiers in medicine · 2023Article
- Monkeypox vaccination-an opportunity for HIV prevention.The lancet. HIV · 2022Article
- Evolving Trends in Late HIV Diagnosis: Increasing Frequency but Improved Survival and Reduced Opportunistic Infections in a 10-Year Hospital-Based Cohort.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Late HIV diagnosis (i.e CD4≤350 cells/µL) is associated with poorer outcomes. However, determinants of long-term mortality and factors influencing immune recovery within the first years after antiretroviral treatment (ART) initiation are poorly defined. Methods: From PISCIS cohort, we included all HIV-positive adults, two-year survivors after initiating ART between 2005-2019. The primary outcome was all-cause mortality according to the two-year CD4 count. We used Poisson regression. The secondary outcome was incomplete immune recovery (i.e., two-year CD4<500 cells/µL). We used logistic regression and propensity score matching. Findings: We included 2,719 participants (16593·1 person-years): 1441 (53%) late presenters (LP) and 1278 non-LP (1145 non-LP with two-year CD4 count >500 cells/µL, reference population). Overall, 113 patients (4·2%) died. Mortality was higher among LP with two-year CD4 count 200-500 cells/µL (aMRR 1·95[95%CI:1·06-3·61]) or <200 cells/µL (aMRR 4·59[2·25-9·37]).Conversely, no differences were observed in participants with two-year CD4 counts >500 cells/µL, regardless of being initially LP or non-LP (aMRR 1·05[0·50-2·21]). Mortality rates within each two-year CD4 strata were not affected by the initial CD4 count at ART initiation (test-interaction, Interpretation: Two-year immune recovery is a good early predictor of long-term mortality in LP after surviving the first high-risk 2 years. Nearly half experienced a favorable immune recovery with a life expectancy similar to non-LP. INSTI-based regimens were associated with higher rates of successful immune recovery and better survival compared to non-INSTI regimens. Funding: Southern-Denmark University, Danish AIDS-foundation, and Region of Southern Denmark.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.